WuXi Biologics (Cayman) Inc. / Fundamentals
Income statement
- Net revenue
€4.25B - Cost of goods sold
€2.53B - Gross profit
€1.72B - SG&A expenses
€503.65M - R&D expenses
€185.50M - EBITDA
€1.35B - D&A
€289.43M - EBIT
€1.06B - Interest expenses
€18.75M - EBT
€1.07B - Tax expenses
€177.55M - Net income
€803.82M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€208.03M - Changes in working capital
-€201.90M - Operating cash flow
€1.18B - Capex
€970.91M - Other investing cash flow
€93.55M - Net investing cash flow
-€853.10M - Total cash dividends paid
€0.00 - Issuance of common stock
€5.42M - Debt repayment
-€39.07M - Other financing cash flow
€258.98M - Net financing cash flow
-€93.88M - Foreign exchange effects
-€5.00M - Net change in cash
€1.76B - Cash at end of period
€985.08M - Free cash flow
€2.15B
Balance sheet
- Cash and cash equivalents
€985.08M - Cash and short-term investments
€1.27B - Total receivables
€688.53M - Inventory
€181.05M - Other current assets
€660.94M - Total current assets
€2.80B - Property, plant & equipment
€3.38B - Goodwill
€182.03M - Intangible assets
€52.63M - Long-term investments
-€3.66M - Other non-current assets
€307.34M - Total non-current assets
€3.97B - Total assets
€6.78B - Accounts payable
€88.90M - Short-term debt
€311.62M - Other current liabilities
€539.56M - Total current liabilities
€1.03B - Long-term debt
€276.14M - Deferred tax liabilities
€11.58M - Other non-current liabilities
€0.00 - Total non-current liabilities
€342.50M - Total liabilities
€1.37B - Common stock
€26.89K - Retained earnings
€1.95B - Other equity
€0.00 - Total equity
€5.41B - Total liabilities and shareholders' equity
€6.78B
Company information
- Market capitalization
€11.23B - Employees
13K - Enterprise Value
€99.83B
Company ratios
- Gross margin
-
40.5% Much better than peer group: -69.0% - EBITDA margin
-
31.8% Much worse than peer group: 1,125.4% - EBIT margin
-
25.0% Much better than peer group: -1,732.9% - EBT margin
-
25.2% Much worse than peer group: 2,396.4% - Net margin
-
18.9% Much better than peer group: -2,012.8% - ROE
-
14.9% Much worse than peer group: 153.4% - ROA
-
11.9% Much better than peer group: -225.5% - Asset turnover
-
62.7% Much better than peer group: 38.2% - FCF margin
-
4.8% Much better than peer group: -1,708.8% - FCF yield
1.8% - Efficiency ratio
68.2% - Net sales per employee
-
€337.88K - Net income per employee
-
€63.92K